Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib

Background

Janus activated kinases (JAKs) are a family of intracellular tyrosine kinases that function as intracellular mediators of multiple cytokines and growth factors involved in the pathogenesis of inflammation and immune-mediated diseases. Many JAK inhibitors (JAKinibs) have been developed over recent years and they have emerged as a new therapeutic class for immune-mediated inflammatory diseases. Tofacitinib (Xeljanz, an anti JAK1-JAK3 agent) and baricitinib (Omlumiant, an anti JAK1-JAK2 agent) are first-generation JAKinibs. Upadacitinib (Rinvoq) is a specific, newer Janus kinase (JAK-1) inhibitor recently approved for the treatment of inflammatory disorders such as rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and psoriatic arthritis [1], [2], [3], [4]. However, few data are available on the use of these recent therapies in the management of ocular inflammation.

Publikationsverlauf

Eingereicht: 26. September 2021

Angenommen: 06. Februar 2022

Artikel online veröffentlicht:
26. April 2022

• References

• 1 Van der Heijde D, Song IH, Pangan AL. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394: 2108-2117
• 2 Smolen JS, Pangan AL, Emery P. et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019; 393: 2303-2311
• 3 Mease PJ, Lertratanakul A, Anderson JK. et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2020; 80: 312-320
• 4 Guttman-Yassky E, Thaçi D, Pangan AL. et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-884
• 5 Dodds EM, Lowder CY, Meisler DM. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm 1999; 7: 85-92
• 6 Heimann H, Bornfeld N, Vij O. et al. Vasoproliferative tumours of the retina. Br J Ophthalmol 2000; 84: 1162-1169
• 7 Bing SJ, Lyu C, Xu B. et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Mol Vis 2020; 26: 641-651
• 8 Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis. Ocul Immunol Inflamm 2019; 27: 1232-1234
• 9 Paley MA, Karacal H, Rao PK. et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2018; 13: 53-55
• 10 Miserocchi E, Giuffrè C, Cornalba M. et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 2020; 39: 847-851